Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CERTAIN: Concurrent Erlotinib and Thoracic Radiation in EGFR-Mutant Stage IV NSCLC
NCT02353741Phase 2Terminated
- Sponsor
- Xinqiao Hospital
- Start
- Apr 2015
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Xinqiao Hospital. Started Apr 2015; status: terminated.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02353741.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02353741.